Drug profile

The FDA adverse-event record for Unspecified Joint Supplement

77 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Unspecified Joint Supplement. See the species affected, top reactions, and outcomes below.

77
adverse-event reports
15.6%
death-coded share
Dog
most-reported species
16
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
77
Total Reports
12
Deaths Reported
15.6%
Death Rate

Active Ingredients

Unspecified Joint Supplement

Administration Routes

OralUnknown

Species Affected

Dog 75
Cat 2

Most Affected Breeds

Retriever - Labrador 21
Retriever - Golden 8
Shepherd Dog - German 6
Terrier (unspecified) 4
Dachshund (unspecified) 4
Boxer (German Boxer) 3
Bulldog 2
Dachshund - Miniature 2
Crossbred Canine/dog 2
Terrier - Bull - American Pit 2

Most Reported Reactions

Vomiting 16
Diarrhoea 14
Lethargy (see also Central nervous system depression in Neurological) 11
Lethargy (see also Central nervous system depression in 'Neurological') 7
Panting 7
Death by euthanasia 6
Lack of efficacy - NOS 6
Proprioception deficit 6
Death 6
Not eating 5
Limb weakness 5
Hind limb paresis 5

Outcome Breakdown

Ongoing
26 (33.8%)
Outcome Unknown
21 (27.3%)
Recovered/Normal
18 (23.4%)
Euthanized
6 (7.8%)
Died
6 (7.8%)

Unspecified Joint Supplement Adverse Event Insights

77 reports name Unspecified Joint Supplement; 12 recorded a death outcome (15.6% of reported events, not a population-level mortality rate). Active ingredient: Unspecified Joint Supplement. Administration routes: Oral, Unknown.

By species: Dog (75 reports), Cat (2 reports). By breed: Retriever - Labrador (21), Retriever - Golden (8), Shepherd Dog - German (6).

Leading clinical signs: Vomiting (16), Diarrhoea (14), Lethargy (see also Central nervous system depression in Neurological) (11), Lethargy (see also Central nervous system depression in 'Neurological') (7). Outcome, 77 coded reports: Ongoing leads at 33.8%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.